Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage.
BACKGROUND
There is little information regarding associations between magnetic resonance imaging (MRI) enhancement and biologic parameters of breast carcinoma. A prospective study was undertaken to correlate MRI dynamic contrast enhancement features with cell proliferative activity, as determined by DNA S-phase percentage.


METHODS
Seventeen patients with invasive breast cancer underwent MRI at 1.5 tesla using a dynamic gadolinium-enhanced spoiled gradient recall echo technique. DNA analysis of samples of the excised lesions was then performed using flow cytometry.


RESULTS
Invasive carcinomas with high DNA S-phase percentages (> or = 6.9%, the median value in this study), a measure of increased cell proliferation, were associated with a peripheral MRI enhancement pattern in 4 of 6 (67%) lesions compared with 0 of 11 carcinomas with lower DNA S-phase percentages (< or = 6.9%) (P = 0.006). There was no significant association between a high DNA S-phase percentage and greater MRI enhancement amplitude, rate, or washout. There was no significant association between aneuploid DNA content and any MRI enhancement feature.


CONCLUSIONS
Increased cell proliferation in invasive breast carcinoma, as determined by high DNA S-phase percentage, is significantly associated with a peripheral MRI enhancement pattern but unrelated to greater MRI enhancement amplitude, rate, or washout.
Stomper
P C
PC
Division of Diagnostic Imaging, Roswell Park Cancer Institute, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, USA.
Herman
S
S
Klippenstein
D L
DL
Winston
J S
JS
Budnick
R M
RM
Stewart
C C
CC
D000328:Adult; D000368:Aged; D000782:Aneuploidy; D001943:Breast Neoplasms / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000473:pathology* / Q000556:secondary; D018275:Carcinoma, Lobular / Q000473:pathology; D002455:Cell Division; D003287:Contrast Media; D004273:DNA, Neoplasm / Q000032:analysis; D004338:Drug Combinations; D005260:Female; D005434:Flow Cytometry; D005682:Gadolinium; D019786:Gadolinium DTPA; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D008207:Lymphatic Metastasis; D008279:Magnetic Resonance Imaging / Q000379:methods; D008536:Meglumine; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives; D011446:Prospective Studies; D016196:S Phase
D003287:Contrast Media; D004273:DNA, Neoplasm; D004338:Drug Combinations; D009942:Organometallic Compounds; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA